Abstract Details

Title Efficacy Analysis of Disease Modifying Treatments in More Than 7000 German Patients with MS

Topic MS and Related Diseases

Presentation(s) P01 - (-)

Poster/Presentation
Number 195

Objective

Background BACKGROUND: We recently showed in a large German cohort of MS patients that immunmodulatory treatment with interferon (IFN) beta or glatirameracetate is effective in the majority of patients with relapsing-remitting MS (RRMS), (Maurer M et al. Eur J Neurol 2011).

Design/Methods DESIGN/METHODS: This was an open-label, retrospective, observational data collection of 9916 patients from 488 German outpatient MS centers. Patients with RRMS diagnosis dating back at least 12 months who either underwent treatment with IFN beta or glatirameracetate or who were untreated during the preceding year were enrolled. 7896 patients received immunomodulatory treatment. Demographic data, type of immunomodulatory treatment, clinical disease activity and MRI findings (T2 lesions and Gd-enhancing lesions) during the last 12 months were evaluated. For evaluation of differences in efficacy the following parameters of clinical disease activity over 12 months were analysed: EDSS: baseline (current EDSS), EDSS 12 months ago (retrospective); relapses (number of relapses and patients with relapses) within the last 12 months; MRI-findings.

Results RESULTS: 7284 treated MS-patients were analysed. 29.6% (n=2154) of the patients received treatment with intramuscular (IM) IFN beta-1a, 25.6% (n=1865) SC IFN beta-1a, 22.5% SC IFN beta-1b (n=1642) and 22.3% (n=1623) with glatirameracetate. The treatment efficacy was similar for all applied DMTs under real life conditions: similar frequency of relapses (no relapse, ? 1 relapses) and proportion of relapsing patients as well as similar EDSS during the last 12 months and MRI-findings were found.

Conclusions CONCLUSIONS: The comparison of the documented efficacy in the open-label, retrospective data collection demonstrates equal efficacy with no significant differences among the available parenteral DMTs in a large MS patient cohort under comparable conditions under real life conditions. Limitations of this study predominantly involve the retrospective character.

Authors/Disclosures
Mathias Maeurer, MD (Universitaetsklinikum) PRESENTER	No disclosure on file
Philipp Knorn, MD (Zentrum Fur Ambulante Neurologie)	No disclosure on file
	No disclosure on file
Gabriele Niemczyk, MD (Biogen Idec Gmbh)	No disclosure on file
Karin Rehberg-Weber	No disclosure on file
	No disclosure on file
Stefan Schwab, MD (U. of Erlangen, Dept. of Neurology)	Dr. Schwab has nothing to disclose.
William M. Carroll, MD, MBBS, FRACP, FAAN (SJOG Neurology)	Dr. Carroll has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Carroll has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Carroll has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.

��ɫ��

��ɫ��